Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects

Biological Psychiatry

Volumn 46, Issue 6, 1999, Pages 839-849

  Von Moltke, Lisa L ^a,b   Greenblatt, David J ^a,b   Grassi, Jeffrey M ^a,b   Granda, Brian W ^a,b   Venkatakrishnan, Karthik ^a,b   Duan, Su Xiang ^a,b   Fogelman, Steven M ^a,b   Harmatz, Jerold S ^a,b   Shader, Richard I ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Citalopram; Cytochromes P450; Drug interactions; Drug metabolism; Selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DIMETHYLNITROSAMINE DEMETHYLASE; KETOCONAZOLE; NORCITALOPRAM; PHENACETIN O DEETHYLASE;

ARTICLE; CONTROLLED STUDY; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; REACTION ANALYSIS;

BIOTRANSFORMATION; CELL LINE, TRANSFORMED; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; CYTOCHROMES; DNA, COMPLEMENTARY; HUMANS; MICROSOMES, LIVER; SEROTONIN UPTAKE INHIBITORS; TRANSFECTION;

EID: 0032857817     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00353-9     Document Type: Article

References (54)

1. Baumann P., Larsen F. The pharmacokinetics of citalopram. Rev Con Pharmacotherapy. 6:1995;287-295.
2. Belpaire F.M., Wijnant P., Temmerman A., Rasmussen B.B., Brøsen K. The oxidative metabolism of metoprolol in human liver microsomes Inhibition by the selective serotonin reuptake inhibitors . Eur J Clin Pharmacol. 54:1998;261-264.
3. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 32:1997;210-258.
4. Bondolfi G., Chautems C., Rochat B., Bertschy G., Baumann P. Non-response to citalopram in depressive patients Pharmacokinetic and clinical consequences of a fluvoxamine augmentation . Psychopharmacology. 128:1996;421-425.
5. Brøsen K., Skjelbo E., Rasmussen B.B., Poulsen H.E., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 45:1993;1211-1214.
6. Court M.H., von Moltke L.L., Shader R.I., Greenblatt D.J. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharmaceut Drug Disp. 18:1997;213-226.
7. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res. 26:1995;179-235.
8. Crespi C.L., Penman B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol. 43:1997;171-188.
9. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 34:1992;262-265.
10. Gram L.F., Hansen M.G.J., Sindrup S.H., et al. Citalopram Interaction studies with levomepromazine, imipramine, and lithium . Ther Drug Monit. 15:1993;18-24.
11. Greenblatt D.J., von Moltke L.L., Harmatz J.S., Shader R.I. Drug interactions with newer antidepressants Role of human cytochromes P450 . J Clin Psychiatry. 59:(supp 15):1998;19-27.
12. Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Inhibition of human Cytochrome P450-3A isoforms by fluoxetine and norfluoxetine In vitro and in vivo studies . J Clin Pharmacol. 36:1996;792-798.
13. Harvey AT, Preskorn SH (1996): Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 16:273-285, 345-355.
14. Hyttel J., Bøgesø K.P., Perregarrd J., Sànchez C. The pharmacological effect of citalopram resides in the (S) -(+) enantiomer. J of Neural Transmission (gen sect). 88:1992;157-160.
15. Inoue K., Yamazaki H., Imiya K., Akasaka S., Guengerich F.P., Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-methenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics. 7:1997;103-113.
16. Jeppesen U., Gram L.F., Vistisen K., Loft S., Poulsen H.E., Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 51:1996;73-78.
17. Ketter T.A., Flockhart D.A., Post R.M., et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 15:1995;387-398.
18. Ko J.-W., Sukhova N., Thacker D., Chen P., Flockhart D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Disp. 25:1997;853-862.
19. Kobayashi K., Chiba K., Yagi T., et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharm Exp Ther. 280:1997;927-933.
20. Kobayashi K., Yamamoto T., Chiba K., Tani M., Ishizaki T., Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol. 40:1995;481-485.
21. Lasker J.M., Wester M.R., Aramsombatdee E., Raucy J.L. Characterization of CYP2C19 and CYP2C9 from human liver Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations . Arch Biochem Biophys. 353:1998;16-28.
22. Milne R.J., Goa K.L. Citalopram A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness . Drugs. 41:1991;450-477.
23. Mitchell P.B. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf. 17:1997;390-406.
24. Newton D.J., Wang R.W., Lu A.Y.H. Cytochrome P450 inhibitors Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes . Drug Metab Disp. 23:1995;154-158.
25. Noble S., Benfield P. Citalopram A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression . CNS Drugs. 8:1997;410-431.
26. Otton S.V., Wu D., Joffe R.T., Cheung S.W., Sellers E.M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 53:1993;401-409.
27. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokin. 32:(supp 1):1997;1-21.
28. Priskorn M., Larsen F., Segonzac A., Moulin M. Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol. 52:1997;241-242.
29. Rasmussen B.B., Mäenpää J., Pelkonen O., et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes Potent inhibition by fluvoxamine . Br J Clin Pharmacol. 39:1995;151-159.
30. Richelson E. Pharmacokinetic drug interactions of new antidepressants A review of the effects on the metabolism of other drugs . Mayo Clin Proc. 72:1997;835-847.
31. Rochat B., Amey M., Gillet M., Meyer U.A., Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 7:1997;1-10.
32. Rochat B., Kosel M., Boss G., Testa B., Gillet M., Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol. 56:1998;15-23.
33. Schmider J., Greenblatt D.J., Fogelman S.M., von Moltke L.L., Shader R.I. Metabolism of dextromethorphan in vitro Involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1 . Biopharmaceut Drug Disp. 18:1997;227-240.
34. Schmider J., Greenblatt D.J., von Moltke L.L., et al. Characterization of six in vitro reactions mediated by human cytochrome P450 Application to the testing of cytochrome P450-directed antibodies . Pharmacology. 52:1996;125-134.
35. Schmider J., Greenblatt D.J., von Moltke L.L., Karsov D., Shader R.I. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro Studies of phenytoin para-hydroxylation . Br J Clin Pharmacol. 44:1997;495-498.
36. Shader R.I., von Moltke L.L., Schmider J., Harmatz J.S., Greenblatt D.J. The clinician and drug interactions - an update. J Clin Psychopharmacol. 16:1996;197-201.
37. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals Studies with liver microsomes of 30 Japanese and 30 Caucasians . J Pharmacol Exp Ther. 270:1994;414-423.
38. Sindrup S.H., Brøsen K., Hansen M.G.J., Aaes-Jørgensen T., Overø K.F., Gram L.F. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 15:1993;11-17.
39. Skjelbo E., Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 34:1992;256-261.
40. Sproule B.A., Naranjo C.A., Bremner K.E., Hassan P.C. Selective serotonin reuptake inhibitors and CNS drug interactions A critical review of the evidence . Clin Pharmacokin. 33:1997;454-471.
41. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro Dominance of CYP 2C19 and 3A4 . J Clin Pharmacol. 38:1998;112-121.
42. Venkatakrishnan K., von Moltke L.L., Duan S.X., Fleishaker J.C., Shader R.I., Greenblatt D.J. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam. J Pharm Pharmacol. 50:1998;265-274.
43. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes Application of the relative activity factor approach . J Pharm Sci. 87:1998;845-853.
44. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole A model system to predict drug interactions in vivo . J Pharmacol Exp Ther. 268:1994;1278-1283.
45. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Harmatz J.S., Shader R.I. Inhibitors of alprazolam metabolism in vitro Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine . Br J Clin Pharmacol. 38:1994;23-31.
46. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine Comparison with other selective serotonin reuptake inhibitor antidepressants . J Clin Psychopharmacol. 15:1995;125-131.
47. von Moltke L.L., Greenblatt D.J., Duan S.X., et al. Phenacetin O-demethylation by human liver microsomes in vitro Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine . Psychopharmacology. 128:1996;398-407.
48. von Moltke L.L., Greenblatt D.J., Harmatz J.S., et al. Triazolam biotransformation by human liver microsomes in vitro Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole . J Pharmacol Exp Ther. 276:1996;370-379.
49. von Moltke L.L., Greenblatt D.J., Duan S.X., et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology. 132:1997;402-407.
50. von Moltke L.L., Greenblatt D.J., Grassi J.M., et al. Protease inhibitors as inhibitors of human cytochromes P450 High risk associated with ritonavir . J Clin Pharmacol. 38:1998;106-111.
51. von Moltke L.L., Greenblatt D.J., Grassi J.M., et al. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A . J Pharm Pharmacol. 50:1998;997-1004.
52. von Moltke L.L., Greenblatt D.J., Schmider J., et al. Midazolam hydroxylation by human liver microsomes in vitro inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents . J Clin Pharmacol. 36:1996;783-791.
53. von Moltke L.L., Greenblatt D.J., Schmider J., Harmatz J.S., Shader R.I. Metabolism of drugs by Cytochrome P450 3A isoforms Implications for drug interactions in psychopharmacology . Clin Pharmacokinet. 29:(supp 1):1995;33-43.
54. von Moltke L.L., Greenblatt D.J., Schmider J., Wright C.E., Harmatz J.S., Shader R.I. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol. 55:1998;113-122.